Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes

References

• Abbvie I. RINVOQ. North Chicago, IL: Abbvie, Inc.
   Google Scholar
• Lin CM, Cooles FA, Isaacs JD. Basic Mechanisms of JAK Inhibition. Mediterr J Rheumatol. 2020;31(Suppl 1):100–104. doi:10.31138/mjr.31.1.100
   PubMedGoogle Scholar
• Lahita RG. Lahita’s Systemic Lupus Erythematosus. Walthum: Elsevier; 2021.
   Google Scholar
• Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. Erratum to: JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77(8):939. doi:10.1007/s40265-017-0736-y
   PubMed Web of Science ®Google Scholar
• Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: current and Future Prospects. Drugs. 2017;77(5):521–546. doi:10.1007/s40265-017-0701-9
   PubMed Web of Science ®Google Scholar
• Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175–187. doi:10.1136/annrheumdis-2017-211555
   PubMed Web of Science ®Google Scholar
• Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2(1):23. doi:10.1186/s41927-018-0031-x
   PubMedGoogle Scholar
• Alexander M, Luo Y, Raimondi G, O’Shea JJ, Gadina M. Jakinibs of all trades: inhibiting cytokine signaling in immune-mediated pathologies. Pharmaceuticals. 2021;15(1):48. doi:10.3390/ph15010048
   Web of Science ®Google Scholar
• McInnes IB, Byers NL, Higgs RE, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21(1):183. doi:10.1186/s13075-019-1964-1
   PubMed Web of Science ®Google Scholar
• Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113–2128. doi:10.1016/S0140-6736(22)00581-5
   PubMed Web of Science ®Google Scholar
• Vermeire S, Colombel JF, Takeuchi K. DOP38 upadacitinib therapy reduces ulcerative colitis symptoms as early as day 1. J Crohns Colitis. 2022;16:087–088. doi:10.1093/ecco-jcc/jjab232.077
   Web of Science ®Google Scholar
• Colombel JF. OP33 Effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe Ulcerative Colitis (UC): results from the UPA Phase 3 programme. J Crohns Colitis. 2022;16:i036–7
   Web of Science ®Google Scholar
• Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393(10188):2303–2311. doi:10.1016/S0140-6736(19)30419-2
   PubMed Web of Science ®Google Scholar
• Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2021;80(3):312–320. doi:10.1136/annrheumdis-2020-218870
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151–2168. doi:10.1016/S0140-6736(21)00588-2
   PubMed Web of Science ®Google Scholar
• Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT Phase III clinical programme. Ann Rheum Dis. 2021;80(3):304–311. doi:10.1136/annrheumdis-2020-218510
   PubMed Web of Science ®Google Scholar
• Din S, Selinger CP, Black CJ, Ford AC. Systematic review with network meta-analysis: risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease. Aliment Pharmacol Ther. 2023;57(6):666–675. doi:10.1111/apt.17379
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, D’Haens GR, Sands BE, et al. Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 years of safety data from the global clinical program. J Crohns Colitis. 2022. doi:10.1093/ecco-jcc/jjac141
   Google Scholar
• Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316–326. doi:10.1056/NEJMoa2109927
   PubMed Web of Science ®Google Scholar
• Burr NE, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut. 2021;71(10):1976–87
   Web of Science ®Google Scholar
• Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(2):161–170. doi:10.1016/S2468-1253(21)00377-0
   PubMed Web of Science ®Google Scholar
• Mohamed MF, Klunder B, Othman AA. Clinical pharmacokinetics of upadacitinib: review of data relevant to the rheumatoid arthritis indication. Clin Pharmacokinet. 2020;59(5):531–544. doi:10.1007/s40262-019-00855-0
   PubMed Web of Science ®Google Scholar